As the Hippo pathway plays an emerging key role in cancer and its pharmacological inhibition in cell lines from other tumour types has shown promising results59, the link between ETV5 and TAZ, and the potential of TAZ as therapeutic target in urothelial carcinoma deserves further investigation. This evidence concerns the gene ETV5 and urothelial carcinoma.